Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new publication by HERC reports the cost-effectiveness results of simvastatin plus ezetimibe for cardiovascular prevention in Chronic Kidney disease (CKD) using data of the Study of Heart and Renal Protection (SHARP). The key result is that while simvastatin plus ezetimibe prevented major atherosclerotic events in SHARP, other less costly statin regimens are cost-effective for reducing cardiovascular risk in CKD.

The article can be found online here.